These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7221359)

  • 1. Kinetics of antimicrobial action.
    Mattie H
    Rev Infect Dis; 1981; 3(1):19-27. PubMed ID: 7221359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo.
    Mattie H; van der Voet GB
    Infection; 1979; 7 Suppl 5():S434-7. PubMed ID: 389820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of antimicrobial activity.
    Vogelman B; Craig WA
    J Pediatr; 1986 May; 108(5 Pt 2):835-40. PubMed ID: 3701535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection.
    Frimodt-Møller N
    Dan Med Bull; 1988 Oct; 35(5):422-37. PubMed ID: 3066588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens.
    Schaper KJ; Schubert S; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing and regrowth of bacteria in vitro: a review.
    Craig WA; Ebert SC
    Scand J Infect Dis Suppl; 1990; 74():63-70. PubMed ID: 2097720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kill kinetics and regrowth pattern of bacteria exposed to antibiotic concentrations simulating those observed in vivo.
    Guggenbichler JP; Semenitz E; König P
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():139-46. PubMed ID: 3980325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of antibacterial activities of antibiotics in vitro and in animal models of infection.
    Zak O; Tosch W; Sande MA
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():273-82. PubMed ID: 3980330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of therapeutic potential by means of a probability model of antimicrobial action.
    Schalkowsky S; Hunt LG
    J Antimicrob Chemother; 1995 Jan; 35(1):31-52. PubMed ID: 7768781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.
    Craig W
    Eur J Clin Microbiol Infect Dis; 1993; 12 Suppl 1():S6-8. PubMed ID: 8477766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.
    Zhi J; Nightingale CH; Quintiliani R
    J Pharm Sci; 1986 Nov; 75(11):1063-7. PubMed ID: 3102718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive parameter of antibacterial efficacy in vivo, based on efficacy in vitro and pharmacokinetics.
    Mattie H
    Scand J Infect Dis Suppl; 1990; 74():133-6. PubMed ID: 2129065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the ID50 values of antibacterial agents in agar.
    Kato T; Kurashige S; Chabbert YA; Mitsuhashi S
    J Antibiot (Tokyo); 1978 Dec; 31(12):1299-303. PubMed ID: 368001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing an antibiotic on the basis of pharmacodynamics.
    Craig WA
    Ear Nose Throat J; 1998 Jun; 77(6 Suppl):7-11; discussion 11-2. PubMed ID: 9674328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics.
    Schentag JJ; Swanson DJ; Smith IL
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():47-57. PubMed ID: 3980336
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice.
    van der Voet GB; Mattie H; van Furth R
    J Antimicrob Chemother; 1985 Nov; 16(5):605-13. PubMed ID: 3935638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.